Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia.
Cellular Reprogramming
/ genetics
DNA Copy Number Variations
DNA Damage
/ genetics
Epigenesis, Genetic
/ genetics
Genome-Wide Association Study
Humans
Leukemia, Prolymphocytic, T-Cell
/ genetics
Lymphocyte Activation
/ genetics
T-Lymphocytes
/ immunology
Transcription, Genetic
/ genetics
Wnt Signaling Pathway
/ physiology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 04 2021
15 04 2021
Historique:
received:
23
09
2020
accepted:
05
04
2021
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
19
11
2021
Statut:
epublish
Résumé
T cell prolymphocytic leukemia (T-PLL) is a rare disease with aggressive clinical course. Cytogenetic analysis, whole-exome and whole-genome sequencing have identified primary structural alterations in T-PLL, including inversion, translocation and copy number variation. Recurrent somatic mutations were also identified in genes encoding chromatin regulators and those in the JAK-STAT signaling pathway. Epigenetic alterations are the hallmark of many cancers. However, genome-wide epigenomic profiles have not been reported in T-PLL, limiting the mechanistic study of its carcinogenesis. We hypothesize epigenetic mechanisms also play a key role in T-PLL pathogenesis. To systematically test this hypothesis, we generated genome-wide maps of regulatory regions using H3K4me3 and H3K27ac ChIP-seq, as well as RNA-seq data in both T-PLL patients and healthy individuals. We found that genes down-regulated in T-PLL are mainly associated with defense response, immune system or adaptive immune response, while up-regulated genes are enriched in developmental process, as well as WNT signaling pathway with crucial roles in cell fate decision. In particular, our analysis revealed a global alteration of regulatory landscape in T-PLL, with differential peaks highly enriched for binding motifs of immune related transcription factors, supporting the epigenetic regulation of oncogenes and genes involved in DNA damage response and T-cell activation. Together, our work reveals a causal role of epigenetic dysregulation in T-PLL.
Identifiants
pubmed: 33859327
doi: 10.1038/s41598-021-87890-9
pii: 10.1038/s41598-021-87890-9
pmc: PMC8050249
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8318Subventions
Organisme : NCI NIH HHS
ID : K23 CA160345
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097274
Pays : United States
Références
Nat Med. 2016 Jun;22(6):632-40
pubmed: 27135738
Nature. 2014 Mar 27;507(7493):455-461
pubmed: 24670763
Cell Rep. 2017 Oct 17;21(3):784-797
pubmed: 29045844
Bioinformatics. 2007 Jan 15;23(2):257-8
pubmed: 17098774
Nat Med. 2014 Oct;20(10):1130-7
pubmed: 25194570
F1000Res. 2016 Jun 20;5:1438
pubmed: 27508061
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Br J Haematol. 2016 Apr;173(2):265-73
pubmed: 26917488
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Blood. 2014 Aug 28;124(9):1460-72
pubmed: 24825865
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Genet. 2019 Oct;51(10):1494-1505
pubmed: 31570894
Blood. 2009 Nov 19;114(21):4675-86
pubmed: 19770358
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Biotechnol. 2010 Oct;28(10):1045-8
pubmed: 20944595
Nature. 2012 Jan 04;481(7381):389-93
pubmed: 22217937
Genes Chromosomes Cancer. 2016 Jan;55(1):82-94
pubmed: 26493028
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23
pubmed: 14973184
J Cancer. 2015 Jul 16;6(9):877-82
pubmed: 26284139
Blood. 2017 Nov 23;130(21):2326-2338
pubmed: 28978570
BMC Genomics. 2014 Apr 15;15:284
pubmed: 24735413
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
Cancer Cell. 2017 Jul 10;32(1):27-41.e4
pubmed: 28625481
EMBO J. 2012 Nov 14;31(22):4318-33
pubmed: 23064151
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
Nucleic Acids Res. 2011 Jan;39(Database issue):D691-7
pubmed: 21067998
Haematologica. 2012 Mar;97(3):328-30
pubmed: 22383743
Nat Genet. 2016 Oct;48(10):1193-203
pubmed: 27526324
Nat Commun. 2018 Dec 17;9(1):5344
pubmed: 30559442
BMC Bioinformatics. 2014 Aug 15;15:280
pubmed: 25128017
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
Cell. 2016 Nov 17;167(5):1369-1384.e19
pubmed: 27863249
Front Oncol. 2018 Jun 27;8:229
pubmed: 29998084
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Bioinformatics. 2010 Apr 1;26(7):873-81
pubmed: 20147302
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Blood. 2012 Aug 23;120(8):1613-23
pubmed: 22645177
Genes Dev. 2013 Dec 15;27(24):2648-62
pubmed: 24285714
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
BMC Bioinformatics. 2013 Mar 09;14:91
pubmed: 23497356
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2911-E2919
pubmed: 28314854
Br J Pharmacol. 2017 Dec;174(24):4701-4715
pubmed: 28703283
Cancer Discov. 2015 Oct;5(10):1058-71
pubmed: 26229090
Nature. 2015 Feb 19;518(7539):337-43
pubmed: 25363779
BMC Genomics. 2017 Dec 21;18(1):985
pubmed: 29268714
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Nat Commun. 2016 Sep 28;7:12983
pubmed: 27677335
Nature. 2012 Oct 25;490(7421):543-6
pubmed: 22992523
Haematologica. 2013 Feb;98(2):269-73
pubmed: 22875623
Nat Commun. 2014 Sep 30;5:5114
pubmed: 25268989
Blood. 2012 Jan 5;119(1):180-7
pubmed: 22065599
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):E4946-53
pubmed: 25369933
Sci Transl Med. 2015 Jun 24;7(293):293ra102
pubmed: 26109102
Nucleic Acids Res. 2016 Jan 4;44(D1):D1023-31
pubmed: 26590405
Mol Biosyst. 2016 Feb;12(2):477-9
pubmed: 26661513
Cancer Discov. 2017 Mar;7(3):322-337
pubmed: 28069569
Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000109
pubmed: 20516126
Nat Commun. 2018 Feb 15;9(1):697
pubmed: 29449575
Front Oncol. 2018 Aug 13;8:317
pubmed: 30151355